|
I bothered posting the study
as many times on this board I have heard the question asked--how do we know whether herceptin when used in the adjuvant setting just delays the onset of metastasis...how will things look five and more years down the road...when can one stop worrying
The answer is not known, but this study at least proposed to look into the matter--I had never seen any such study before-- although the study was poorly executed, both statistically and by lumping all breast cancer patients together.
Perhaps her2 has only been measured routinely (and only in some centers in some countries) for a few years, but the study could also have been divided by pre vs postmenopausal, ER+ vs ER- etc.
I particularly dislike studies performed by doing Medline searches of clinical trials and them lumping them all together. Not just comparing apples with oranges, but trying to make sense, or at least a point, with fruit salad (and a very varied one at that)
|